ATE428405T1 - Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger - Google Patents

Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger

Info

Publication number
ATE428405T1
ATE428405T1 AT05718991T AT05718991T ATE428405T1 AT E428405 T1 ATE428405 T1 AT E428405T1 AT 05718991 T AT05718991 T AT 05718991T AT 05718991 T AT05718991 T AT 05718991T AT E428405 T1 ATE428405 T1 AT E428405T1
Authority
AT
Austria
Prior art keywords
drug carriers
modified active
hydrogel matrices
active release
anionic hydrogel
Prior art date
Application number
AT05718991T
Other languages
English (en)
Inventor
Gaetano Giammona
Delia Mandracchia
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE428405T1 publication Critical patent/ATE428405T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT05718991T 2004-04-01 2005-02-16 Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger ATE428405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000168A ITRM20040168A1 (it) 2004-04-01 2004-04-01 Composizione a rilascio modificato ph dipendente.
PCT/IT2005/000081 WO2005094792A1 (en) 2004-04-01 2005-02-16 Anionic hydrogel matrices with ph dependent modified release as drug carriers

Publications (1)

Publication Number Publication Date
ATE428405T1 true ATE428405T1 (de) 2009-05-15

Family

ID=34961555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05718991T ATE428405T1 (de) 2004-04-01 2005-02-16 Anionische hydrogelmatrizes mit ph-abhängiger modifizerter wirkstofffreisetzung als arzneimittelträger

Country Status (20)

Country Link
US (1) US20070166383A1 (de)
EP (1) EP1729732B1 (de)
JP (1) JP2007530666A (de)
KR (1) KR20060133578A (de)
CN (1) CN1913875B (de)
AT (1) ATE428405T1 (de)
AU (1) AU2005228716B2 (de)
BR (1) BRPI0509475A (de)
CA (1) CA2551797A1 (de)
CY (1) CY1109209T1 (de)
DE (1) DE602005013935D1 (de)
DK (1) DK1729732T3 (de)
ES (1) ES2325626T3 (de)
HR (1) HRP20090329T1 (de)
IT (1) ITRM20040168A1 (de)
PL (1) PL1729732T3 (de)
PT (1) PT1729732E (de)
RS (1) RS51178B (de)
SI (1) SI1729732T1 (de)
WO (1) WO2005094792A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4746883B2 (ja) * 2005-01-28 2011-08-10 リンテック株式会社 ハイドロゲル基剤、パップ剤基剤、パップ剤及び水性ゲルシート
EP2379697A2 (de) 2008-12-31 2011-10-26 3M Innovative Properties Company Probenahmevorrichtungen und verfahren zur aufkonzentration von mikroorganismen
EP2379226B1 (de) 2008-12-31 2016-04-20 3M Innovative Properties Company Erfassung von lebender biolast unter verwendung von mikropartikeln
WO2011082258A2 (en) 2009-12-30 2011-07-07 Regents Of The University Of Minnesota Bone cement and method
BR112012016119B1 (pt) 2009-12-30 2020-04-28 3M Innovative Properties Co método de detecção de células em uma amostra, dispositivo unitário de preparação e detecção de amostra e kit
WO2011090349A2 (ko) * 2010-01-21 2011-07-28 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
KR101228106B1 (ko) * 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
CN103330702B (zh) * 2013-07-02 2016-03-02 江苏长泰药业有限公司 含有拟交感神经胺盐和诱导凝胶体系的医药组合物
CN108452291A (zh) * 2018-07-04 2018-08-28 西南大学 用天然丝胶蛋白治疗溃疡性结肠炎的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071508A (en) * 1975-02-11 1978-01-31 Plastomedical Sciences, Inc. Anionic hydrogels based on hydroxyalkyl acrylates and methacrylates
IT1284661B1 (it) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali.
DE19653631A1 (de) * 1996-12-20 1998-06-25 Basf Coatings Ag Verfahren zum Herstellen von durch Strahlung vernetzbaren polymeren Acryl- oder Methacrylsäureestern
EP0986408B1 (de) * 1997-06-03 2005-05-11 Innogenetics N.V. Neue arzneimittel auf der basis von polymeren aus mit methacrylamid modifizierter gelatine
IL144597A0 (en) * 1999-02-03 2002-05-23 Powderject Res Ltd Hydrogel particle formulations
US6547182B2 (en) * 2001-07-19 2003-04-15 Aerojet-General Corporation Solid rocket motor bolted thrust takeout structure
US7204997B2 (en) * 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto

Also Published As

Publication number Publication date
CN1913875A (zh) 2007-02-14
PL1729732T3 (pl) 2009-09-30
HRP20090329T1 (hr) 2009-09-30
RS51178B (sr) 2010-10-31
ITRM20040168A1 (it) 2004-07-01
SI1729732T1 (sl) 2009-08-31
BRPI0509475A (pt) 2007-09-11
CA2551797A1 (en) 2005-10-13
DK1729732T3 (da) 2009-08-10
AU2005228716A1 (en) 2005-10-13
WO2005094792A1 (en) 2005-10-13
DE602005013935D1 (de) 2009-05-28
JP2007530666A (ja) 2007-11-01
EP1729732B1 (de) 2009-04-15
EP1729732A1 (de) 2006-12-13
CN1913875B (zh) 2011-08-31
US20070166383A1 (en) 2007-07-19
CY1109209T1 (el) 2014-07-02
AU2005228716B2 (en) 2010-07-15
PT1729732E (pt) 2009-07-02
KR20060133578A (ko) 2006-12-26
ES2325626T3 (es) 2009-09-10

Similar Documents

Publication Publication Date Title
CY1109209T1 (el) Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
TW200800967A (en) Benzimidazole thiophene compounds
UA100851C2 (ru) Средство для борьбы с паразитами на животных
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
EP2308870A3 (de) 2-Oxo-1-pyrrolidin-Derivate, Verfahren zu deren Herstellung und deren Verwendungen
TR201911270T4 (tr) Polimerik mirsen bileşimleri.
TW200613500A (en) Michael addition compositions
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
DE602006012694D1 (de) Benzimidazolthiophenverbindungen als plk-modulatoren
UA100850C2 (ru) Средство для борьбы с паразитами на животных
AR055615A1 (es) Dispersiones amorfas solidas
MY145555A (en) Active compound-containing solid moulded bodies for external use against parasites on animals
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
MX2007013327A (es) Formulaciones de liberacion prolongada.
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
WO2007025994A3 (fr) Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant
TNSN07438A1 (en) Prolonged release formulation of active principles having a ph-dependent solubility
UY28809A1 (es) Composiciones diuréticas de liberación prolongada

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1729732

Country of ref document: EP